The company said it raised its FY25 non-GAAP diluted EPS outlook to $8.15 to $8.20 from the prior $8.05 to $8.15 and narrowed the range, citing a 9% growth at the midpoint.

1. 01

   The company said it raised its FY25 non-GAAP diluted EPS outlook to $8.15 to $8.20 from the prior $8.05 to $8.15 and narrowed the range, citing a 9% growth at the midpoint.

2. 02

   Cardinal Health set preliminary non-GAAP diluted EPS guidance for FY26 at $9.10 to $9.30 (13% growth at the midpoint). It said it reaffirmed its FY26 to FY28 long-term target of 12% to 14% compound annual growth rate (CAGR).

3. 03

   The company said it raised its FY25 adjusted free cash flow outlook to ~$2 billion from ~$1.5 billion. It also said its FY26 outlook is $2.75B to $3.25B, and its FY26 to FY28 total is at least $10B.

4. 04

   The company said it expects baseline share repurchases of at least $750 million per year over the next 3 years, above its previous annual baseline of $500 million. It also said it plans to invest at least $600 million per year in capital expenditures.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.